Information on treatment success rates for AML in adults can be found in Treatment Response Rates for Acute Myeloid Leukemia. Our team is made up of doctors and oncology certified nurses with deep ...

CLL accounts for about 1 in 3 new cases of leukemia in the US, and about 1% of cancers overall. CLL is slightly more common among men than women, but the average lifetime risk of getting CLL for both ...

Pirtobrutinib (brand name Jaypirca) could reduce progression or death risk by 46% in patients with chronic lymphocytic ...

Helen Jackson's toddler, misdiagnosed with flu, was later found to have acute lymphoblastic leukemia after her condition ...

The cancer death rate continues to decline in the U.S. but new cases are rising among women, potentially undermining p ...

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings ...

Among patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), valemetostat appears to induce durable responses, according to research published in The Lancet Oncology.

The FDA has approved Calquence (acalabrutinib) for use in combination with bendamustine and rituximab to treat adults with previously untreated MCL who are ineligible for transplant.

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. By selectively depleting CD19-positive B-cells, ...

The cancer death rate declined by more than one-third over a three-decade period in the United States, though incidence rates ...

Childhood cancer survivors had greater than twofold increased risk of invasive skin and ocular melanoma (95% CI 1.6-2.4) ...

TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa Pharmaceuticals, Inc. ("Handa") (6620.TWO) announced that its U.S.